Press – August 17, 2017

Witty Health Inc. announces the initiation of clinical development of a novel Fulvestrant Cancer Treatment Platform for metastatic breast cancer

Houston, TX – August 14, 2017 – Witty Health Inc., a technology company focused on cancer drug toxicity monitoring and treatment pathways, today announced the initiation of the clinical development of software-enabled Fulvestrant product for treating certain types of breast cancer.

Witty Health’s Cancer Treatment Platform (CTP™) is custom built for a particular drug based on its toxicity profile. CTP™ helps monitor drugs’ toxicity and patients’ vitals in real-time to improve patient’s Quality of Life (QoL) and potential outcomes associated with the drug.

Fulvestrant (marketed under brand name Faslodex® by AstraZeneca) is an Estrogen Receptor Modulator. Fulvestrant is approved for the treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy and for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. Faslodex® is expected to clock over $1.1 billion in sales by 2020.

“We are excited to initiate the development of first ever software-enabled drug through the formal regulatory approval,” said Co-Founder Ram Sesha. “We believe the treatment with Fulvestrant Cancer Treatment Platform will result in better Quality of Life (QoL) and improved outcomes than with the parent drug-Faslodex. Our product provides better option than Faslodex® which is facing generic competition in early 2019. To seek a Fast Track designation, the development is in continual collaboration with Food and Drug Administration (FDA).”

“The current cancer treatment model without monitoring patient’s condition between office visits is not working. Fulvestrant Cancer Treatment Platform (FCTP™) is designed to improve outcomes associated with Fulvestrant. This is more so when Fulvestrant is used in combination with CDK 4/6 inhibitors Ibrance®, Abemaciclib, and Kisqali®.  Further, we believe our product can significantly reduce preventable health care costs by reducing ER visits and hospitalizations due to symptom exacerbations as well,” said Dr. Karthik Koduru, the Chief Oncologist of Witty Health.

Witty Health’s Cancer Treatment Platform (CTP™) can be connected with up to eight devices: a wireless weighing scale, blood pressure cuff, pulse oximeter, stethoscope, thermometer, multi-scope camera, ECG and blood glucose monitor depending on the drug. Cancer Treatment Platform (CTP™) includes drug specific toxicity pathways to help oncologists address a specific toxicity effectively and promptly to improve Quality of Life (QoL) and potentially improve outcomes of the treatment. The Cancer Treatment Platform (CTP™) is custom built for any cancer drug including Checkpoint inhibitors; Opdivo, Keytruda®, Imfinzi, TecentriQ® and Bavencio, CDK 4/6 inhibitors: Ibrance®, Abemaciclib, and Kisqali®, PARP inhibitors; Lynparza, Zejula and Rubraca and for any pain medication. Like other combination strategies; I-O/I-O, I-O/chemotherapy, I-O/targeted therapies and I-O/radiation therapies, Cancer Treatment Platform (CTP™) provides an additional combination option to improve QoL and outcomes. A pending patent application protects Fulvestrant Cancer Treatment Platform.

Witty Health Inc was established with the aim of finding new models to combat chronic care diseases through an intelligent, remote health risk monitoring technology. The company uses the InstaMD platform which includes: a telemedicine-based remote clinic, home health monitoring, patient diagnosis, and messaging application modules. Witty Health Inc. has assembled an experienced management team and owned by a number of several outstanding physician/oncology leaders.

For further information about Witty Health and its Cancer Treatment Platform (CTP™), please visit www.wittyhealth.com

About Witty Health

Witty Health, Inc. (www.wittyhealth.com) is a Houston, TX-based technology company focusing on intelligence-powered, real-time health risk monitoring for clinical prevention. Witty Health, privately held by employees and outstanding physician/oncology leaders, is redefining the immunotherapy-based cancer treatments through the development and commercialization of its proprietary Cancer Treatment Platform (CTP™). ­­­­­­­

 

Media Contact:
Contact Person: Ram Sesha
Witty Health Inc.
5850, San Felipe, Suite 500
Houston. TX 77057

Phone: (713) 470-2580
Email: info@wittyhealth.com

www.wittyhealth.com

This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.

Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest investor report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.